Acenaphthene

Acenaphthene

SCHEMBL598252

c1cc2c3c(cccc3c1)CC2.c1cc2c3c(cccc3c1)CC2

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.57
CYP3A4 P08684 3/20 0.57
HSD17B10 Q99714 7/20 0.56
LMNA P02545 2/20 0.56
ALDH1A1 P00352 12/20 0.50
HPGD P15428 9/20 0.50
CYP1A2 P05177 3/20 0.50
CYP1A1 P04798 1/20 0.50
CYP1B1 Q16678 1/20 0.50
KDM4E B2RXH2 5/20 0.46
GAA P10253 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 2/20 0.46
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
TYMS P04818 1/20 0.41
CYP2C19 P33261 1/20 0.41
ATM Q13315 2/20 0.41
MAPK1 P28482 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acenaphthene SCHEMBL3416108 1.00 TSHR (0.57) TSHRCYP3A4HSD17B10LMNAALDH1A1
Acenaphthene SCHEMBL28028969 1.00 TSHR (0.57) TSHRCYP3A4HSD17B10LMNAALDH1A1
Acenaphthene SCHEMBL29386207 1.00 TSHR (0.57) TSHRCYP3A4HSD17B10LMNAALDH1A1
Acenaphthene SCHEMBL1162573 1.00 TSHR (0.57) TSHRCYP3A4HSD17B10LMNAALDH1A1
Acenaphthene SCHEMBL9017 1.00 TSHR (0.57) TSHRCYP3A4HSD17B10LMNAALDH1A1
Acenaphthene SCHEMBL29182301 0.97 TSHR (0.55) TSHRCYP3A4HSD17B10LMNAALDH1A1
Acenaphthene SCHEMBL27885324 0.97 TSHR (0.55) TSHRCYP3A4HSD17B10LMNAALDH1A1
Acenaphthene SCHEMBL30729939 0.97 TSHR (0.55) TSHRCYP3A4HSD17B10LMNAALDH1A1
Acenaphthene SCHEMBL29586283 0.97 TSHR (0.55) TSHRCYP3A4HSD17B10LMNAALDH1A1
Acenaphthene SCHEMBL27601829 0.97 TSHR (0.55) TSHRCYP3A4HSD17B10LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109813827-A Study the device and test method that persistence organic pollutant Low Temperature Solid-Phase generates 中国科学院大连化学物理研究所 2019-05-28 CN claimed
CN-104558361-B Preparation method and application of hydrophilic polyaromatic hydrocarbon molecularly imprinted solid phase extraction filler 中国科学院烟台海岸带研究所 2017-05-17 CN claimed
CN-104558361-A Preparation method and application of hydrophilic polyaromatic hydrocarbon molecularly imprinted solid phase extraction filler YANTAI INST COASTAL ZONE RES CAS 2015-04-29 CN claimed
CN-106862262-A A kind of soil biochemistry complex repairation agent and preparation method and application 四川大学 2017-06-20 CN disclosed
CN-104672954-B Low polycyclic aromatic hydrocarbon content furnace black production method and colour carbon black product 安徽黑钰颜料新材料有限公司 2017-06-06 CN disclosed
CN-104558361-B Preparation method and application of hydrophilic polyaromatic hydrocarbon molecularly imprinted solid phase extraction filler 中国科学院烟台海岸带研究所 2017-05-17 CN disclosed
CN-106645455-A Gas chromatography tandem mass spectrometry detection method for 18 polycyclic aromatic hydrocarbons in plastic products 中华人民共和国台州出入境检验检疫局 2017-05-10 CN disclosed
CN-105733636-A Heat integration distillation deep processing method and device of absorber oil 天津中科拓新科技有限公司 2016-07-06 CN disclosed
CN-104672954-A Production method of furnace carbon black with low polyaromatic hydrocarbon content and pigment carbon black product thereof BLACK DIAMOND MATERIAL SCIENCE CO LTD 2015-06-03 CN disclosed
CN-104558361-A Preparation method and application of hydrophilic polyaromatic hydrocarbon molecularly imprinted solid phase extraction filler YANTAI INST COASTAL ZONE RES CAS 2015-04-29 CN disclosed
CN-102405200-B Novel organic compound, light-emitting device, and image display apparatus CANON KK 2014-12-10 CN disclosed
CN-1561872-A Method for producing diacetate fiber tows of chitosan modified cigarette UNIV JIANGNAN (CN) 2005-01-12 CN disclosed
US-20040214844-A1 N4-acylcytosine nucleosides for treatment of viral infections GILEAD PHARMASSET LLC 2004-10-28 US disclosed
EP-1461041-A2 PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES Pharmasset Ltd. (BB) 2004-09-29 EP disclosed
US-20030176319-A1 For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts GILEAD PHARMASSET LLC 2003-09-18 US disclosed
US-20030162992-A1 Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde PHARMASSET, INC. 2003-08-28 US disclosed
WO-2003063771-A2 N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS PHARMASSET LTD. (BB) 2003-08-07 WO disclosed
WO-2003051298-A2 PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES PHARMASSET LTD. (BB) 2003-06-26 WO disclosed
WO-2003051306-A2 N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS PHARMASSET LTD. (BB) 2003-06-26 WO disclosed
US-5600958-A Shipper HENNING STEVE (US) 1997-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176319-A1 For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts ENTPD5, CDA, ADA TSHR 4374/4885CYP3A4 740/4885HSD17B10 631/4885
US-20040214844-A1 N4-acylcytosine nucleosides for treatment of viral infections ENTPD5, DUT, PNP TSHR 4420/4885CYP3A4 826/4885HSD17B10 1057/4885
US-20030162992-A1 Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde DERA, DPYD, DHPS TSHR 3766/4885CYP3A4 1525/4885HSD17B10 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.